Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin versus glimepiride for early renal protection in newly diagnosed type 2 diabetes
ChiCTR2000037951Phase 4Completed
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Sep 2019
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of canagliflozin and glimepiride in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoints: Kidney tissue oxygenation status and Kidney blood perfusion level. Started Sep 2019; status: completed.
02
Drugs
canagliflozinglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000037951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037951.